APP and Alzheimer disease: The involvement of CDR1-AS in AD is further support by in vitro experiments showing that the overexpression of this circRNA promotes degradation of APP and beta-secretase 1 (BACE1) through proteasomal and lysosomal pathways, thus, reducing the accumulation of AD-amyloid peptides [63].